Dr Julian Lewis: To ask the Secretary of State for Health and Social Care, pursuant to his oral contribution of 19 October 2020, Official Report, column 785 on vaccine production schedules, what the respective (a) starting dates were and (b) planned end dates are for the current trials of the (i) AstraZeneca, (ii) Imperial College and (iii)  Novavax vaccines; and if he will list any factors, other than adverse reactions by subjects receiving these vaccines on an experimental basis, which may delay the completion of the trials beyond the planned end dates.  [106210]

[Due for Answer on 23 October.]

ANSWER

The Parliamentary Under Secretary of State, Department for Business, Energy and Industrial Strategy (Amanda Solloway): The AstraZeneca and University of Oxford vaccine started clinical trials in April 2020 and is currently in phase 2/3. The Imperial College London vaccine started clinical trials in June 2020 and is currently in phase 1/2. The Novavax vaccine clinical trials started in May 2020 and is currently in phase 3. The end date of each trial is dependent on the clinical results and the data. Government is working closely with vaccine developers to monitor progress of clinical trials.